In preclinical testing, the experimental compound GPPD simultaneously improved fat accumulation, inflammation, liver injury, and fibrosis while demonstrating an encouraging safety profile with no significant toxicity.

From the articlePromising therapy for fatty liver disease reduces fat, inflammation, and scarring in preclinical models